Cavalieri S, et al. - Among patients who received dacomitinib (pan-HER inhibitor) or platinum-based chemotherapy with cetuximab (CT-cet) from 2010 to 2016 for recurrent or metastatic (R/M) skin squamous cell carcinoma (sSCC), researchers focused on the possible role of PD-L1 expression in predicting response to anti-epidermal growth factor receptor (EGFR) agents. This study included 28 patients (19 treated with dacomitinib and 9 with CT-cet). Findings revealed that better progression-free survival was predicted by PD-L1 expression in the microenvironment. The interrelations between the EGFR and PD-1/PD-L1 pathways could be better understood with the help of the combination of EGFR inhibitors and immune checkpoint blocker.